Search
Depression Paid Clinical Trials in New Mexico
A listing of 3 Depression clinical trials in New Mexico actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Depression
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of New Mexico currently has 3 active clinical trials seeking participants for Depression research studies. These trials are conducted in various cities, including Albuquerque, Santa Fe, Las Cruces and Farmington.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
COVID-19 Vaccine Clinical Trial (Compensation Provided)
Recruiting
Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.
Qualified participants may receive compensation for time and travel.
Qualified participants may receive compensation for time and travel.
Conditions:
Healthy
Vaccine
COVID19
COVID-19
COVID-19 Vaccine
Featured Trial
Heart failure clinical study is now enrolling
Recruiting
Are you interested in a clinical study exploring an investigational medicine for heart failure, also known as HF? The MARITIME-HF clinical study is testing an investigational medicine to see if it can reduce HF-related symptoms and risk of hospitalization in people living with HF and obesity.
Researchers are focused on developing a potential option for reducing HF-related symptoms. By participating, you may contribute to research that may offer benefits for those in the future in need of a different way to manage their HF.
Answer just a few questions to submit your information and see if you may qualify
Researchers are focused on developing a potential option for reducing HF-related symptoms. By participating, you may contribute to research that may offer benefits for those in the future in need of a different way to manage their HF.
Answer just a few questions to submit your information and see if you may qualify
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
Featured Trial
Obesity (w/ CVD or T2DM) Clinical Study
Recruiting
A clinical study for people that suffer with Obesity (w/ CVD or T2DM)
Conditions:
Obesity (w/ CVD or T2DM)
Featured Offer
Lose Weight with Tirzepatide
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
Conditions:
Overweight
Overweight and Obesity
Featured Trial
Type 2 Diabetes (Hard-to-Control) Clinical Study
Recruiting
Studying an Investigational Medication for Adults with Hard-to-Control Type 2 Diabetes.
We're reaching out to let you know that a type 2 diabetes study is looking for participants to help advance investigational weight management treatment options.
Participants who qualify and enroll may receive compensation for related time and travel.
We're reaching out to let you know that a type 2 diabetes study is looking for participants to help advance investigational weight management treatment options.
Participants who qualify and enroll may receive compensation for related time and travel.
Conditions:
Type 2 Diabetes (Hard-to-Control)
Diabetes Mellitus
Type 2
Type 2 Diabetes
Diabete Type 2
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of New Mexico - Psychiatric Center, Albuquerque, New Mexico
Conditions: Treatment Resistant Depression
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: University of New Mexico Health Sciences Center Albuquerque, Albuquerque, New Mexico
Conditions: Bipolar I Disorder, Depression
Amplitude Titration to Improve ECT Clinical Outcomes
Recruiting
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT:
H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2).
H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/03/2025
Locations: University of New Mexico Health Science Center, Albuquerque, New Mexico